5. D. Rajon, W.E. Bolch, R.W. Howell, Survival of tumor and normal cells upon targeting with
electron-emitting radionuclides. Med. Phys. 40, 014101 (2013)
6. K.M. Prise, G. Schettino, M. Folkard, K.D. Held, New insights on cell death from radiation
exposure. Lancet. Oncol. 6, 520–528 (2005)
7. J.P. Pouget, I. Navarro-Teulon, M. Bardiès, N. Chouin, G. Cartron, A. Pèlegrin et al., Clinical
radioimmunotherapy–the role of radiobiology. Nat. Rev. Clin. Oncol. 8(12), 720–734 (2011)
8. M.C. Hernandez, S.J. Knox, Radiobiology of radioimmunotherapy: targeting CD20 B-cell
antigen in non-Hodgkin’s lymphoma. Int. J. Radiation Oncol. Biol. Phys. 59, 1274–1287 (2004)
9. C. LA Friesen, J. Kotzerke, I. Buchmann, S.N. Reske, K.M. Debatin, Beta-irradiation used for
systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in
leukaemia cells. Eur. J. Nucl. Med. Mol. Imaging 30, 1251–1261 (2003)
10. D.E. Milenic, E.D. Brady, M.W. Brechbiel, Antibody-targeted radiation cancer therapy. Nat.
Rev. Drug Discov. 3, 488–499 (2004)
11. J.P. Pouget, S.J. Mather, General aspects of the cellular response to low- and high-LET
radiation. Eur. J. Nucl. Med. 28(4), 541–561 (2001)
12. G. Sgouros, J.C. Roeske, M.R. McDevitt, S. Palm, B.J. Allen, D.R. Fisher et al., MIRD
Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for
targeted radionuclide therapy. J. Nucl. Med. 51(2), 311–328 (2010)
13. G. Ferro-Flores, B.E. Ocampo-García, C.L. Santos-Cuevas, E. Morales-Avila, E.
Azorín-Vega, Multifunctional radiolabeled nanoparticles for targeted therapy. Curr. Med.
Chem. 21(1), 124–138 (2014)
14. A. Soundararajan, G.D. Dodd 3rd, A. Bao, W.T. Phillips, L.M. McManus, T.J. Prihoda et al.,
Chemoradionuclide therapy with
186
Re-labeled liposomal doxorubicin in combination with
radiofrequency ablation for effective treatment of head and neck cancer in a nude rat tumor
xenograft model. Radiology 261, 813–823 (2011)
15. D.V.S. Pissuwan, M.B. Cortie, Therapeutic possibilities of plasmonically heated gold
nanoparticles. Trends Biotechnol. 24, 62–67 (2006)
16. R.M. Sharkey, D.M. Goldenberg, Novel radioimmunopharmaceuticals for cancer imaging
and therapy. Curr. Opin. Investig. Drugs 9, 1302–1316 (2008)
17. P. Cherukuri, E.S. Glazer, S.A. Curley, Targeted hyperthermia using metal nanoparticles.
Adv. Drug Del. Rev. 62, 339–345 (2010)
18. A. Vilchis-Juárez, G. Ferro-Flores, C. Santos-Cuevas, E. Morales-Avila, B. Ocampo-García,
L. Díaz-Nieto et al., Molecular targeting radiotherapy with cyclo-RGDFK(C) peptides
conjugated to
177
Lu-labeled gold nanoparticles in tumor-bearing mice. J. Biomed.
Nanotechnol. 10(3), 393–404 (2014)
19. M. de Visser, W.M. van Weerden, C.M. de Ridder, S. Reneman, M. Melis, E.P. Krenning
et al., Androgen-dependent expression of the gastrin-releasing peptide receptor in human
prostate tumor xenografts. J. Nucl. Med. 48(1), 88–93 (2007)
20. N. Jiménez-Mancilla, G. Ferro-Flores, C. Santos-Cuevas, B. Ocampo-García, M.
Luna-Gutiérrez, E. Azorín-Vega et al., Multifunctional targeted therapy system based on
99m
Tc/
177
Lu-labeled gold nanoparticles-Tat(49-57)-Lys(3) -bombesin internalized in nuclei of
prostate cancer cells. J. Label. Comp. Radiopharm. 56(13), 663–671 (2013)
21. N. Bertrand, J. Wu, X. Xu, N. Kamaly, O.C. Farokhzad, Cancer nanotechnology: the impact
of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 66,
2–25 (2014)
22. H. Maeda, Toward a full understanding of the EPR effect in primary and metastatic tumors as
well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. 91, 3–6 (2015)
23. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, K. Hori, Tumor vascular permeability and the EPR
effect in macromolecular therapeutics: a review. J. Control Release. 65, 271–284 (2000)
24. M.D. Shultz, J.D. Wilson, C.E. Fuller, J. Zhang, H.C. Dorn, P.P. Fatouros,
Metallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging
in a murine orthotopic xenograft model. Radiology 261(1), 136–143 (2011)
25. H. Xie, B. Goins, A. Bao, Z.J. Wang, W.T. Phillips, Effect of intratumoral administration on
biodistribution of
64
Cu-labeled nanoshells. Int. J. Nanomed. 7, 2227–2238 (2012)
23 Therapeutic/Theranostic Use of Radionanomedicine
441
electron-emitting radionuclides. Med. Phys. 40, 014101 (2013)
6. K.M. Prise, G. Schettino, M. Folkard, K.D. Held, New insights on cell death from radiation
exposure. Lancet. Oncol. 6, 520–528 (2005)
7. J.P. Pouget, I. Navarro-Teulon, M. Bardiès, N. Chouin, G. Cartron, A. Pèlegrin et al., Clinical
radioimmunotherapy–the role of radiobiology. Nat. Rev. Clin. Oncol. 8(12), 720–734 (2011)
8. M.C. Hernandez, S.J. Knox, Radiobiology of radioimmunotherapy: targeting CD20 B-cell
antigen in non-Hodgkin’s lymphoma. Int. J. Radiation Oncol. Biol. Phys. 59, 1274–1287 (2004)
9. C. LA Friesen, J. Kotzerke, I. Buchmann, S.N. Reske, K.M. Debatin, Beta-irradiation used for
systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in
leukaemia cells. Eur. J. Nucl. Med. Mol. Imaging 30, 1251–1261 (2003)
10. D.E. Milenic, E.D. Brady, M.W. Brechbiel, Antibody-targeted radiation cancer therapy. Nat.
Rev. Drug Discov. 3, 488–499 (2004)
11. J.P. Pouget, S.J. Mather, General aspects of the cellular response to low- and high-LET
radiation. Eur. J. Nucl. Med. 28(4), 541–561 (2001)
12. G. Sgouros, J.C. Roeske, M.R. McDevitt, S. Palm, B.J. Allen, D.R. Fisher et al., MIRD
Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for
targeted radionuclide therapy. J. Nucl. Med. 51(2), 311–328 (2010)
13. G. Ferro-Flores, B.E. Ocampo-García, C.L. Santos-Cuevas, E. Morales-Avila, E.
Azorín-Vega, Multifunctional radiolabeled nanoparticles for targeted therapy. Curr. Med.
Chem. 21(1), 124–138 (2014)
14. A. Soundararajan, G.D. Dodd 3rd, A. Bao, W.T. Phillips, L.M. McManus, T.J. Prihoda et al.,
Chemoradionuclide therapy with
186
Re-labeled liposomal doxorubicin in combination with
radiofrequency ablation for effective treatment of head and neck cancer in a nude rat tumor
xenograft model. Radiology 261, 813–823 (2011)
15. D.V.S. Pissuwan, M.B. Cortie, Therapeutic possibilities of plasmonically heated gold
nanoparticles. Trends Biotechnol. 24, 62–67 (2006)
16. R.M. Sharkey, D.M. Goldenberg, Novel radioimmunopharmaceuticals for cancer imaging
and therapy. Curr. Opin. Investig. Drugs 9, 1302–1316 (2008)
17. P. Cherukuri, E.S. Glazer, S.A. Curley, Targeted hyperthermia using metal nanoparticles.
Adv. Drug Del. Rev. 62, 339–345 (2010)
18. A. Vilchis-Juárez, G. Ferro-Flores, C. Santos-Cuevas, E. Morales-Avila, B. Ocampo-García,
L. Díaz-Nieto et al., Molecular targeting radiotherapy with cyclo-RGDFK(C) peptides
conjugated to
177
Lu-labeled gold nanoparticles in tumor-bearing mice. J. Biomed.
Nanotechnol. 10(3), 393–404 (2014)
19. M. de Visser, W.M. van Weerden, C.M. de Ridder, S. Reneman, M. Melis, E.P. Krenning
et al., Androgen-dependent expression of the gastrin-releasing peptide receptor in human
prostate tumor xenografts. J. Nucl. Med. 48(1), 88–93 (2007)
20. N. Jiménez-Mancilla, G. Ferro-Flores, C. Santos-Cuevas, B. Ocampo-García, M.
Luna-Gutiérrez, E. Azorín-Vega et al., Multifunctional targeted therapy system based on
99m
Tc/
177
Lu-labeled gold nanoparticles-Tat(49-57)-Lys(3) -bombesin internalized in nuclei of
prostate cancer cells. J. Label. Comp. Radiopharm. 56(13), 663–671 (2013)
21. N. Bertrand, J. Wu, X. Xu, N. Kamaly, O.C. Farokhzad, Cancer nanotechnology: the impact
of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 66,
2–25 (2014)
22. H. Maeda, Toward a full understanding of the EPR effect in primary and metastatic tumors as
well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. 91, 3–6 (2015)
23. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, K. Hori, Tumor vascular permeability and the EPR
effect in macromolecular therapeutics: a review. J. Control Release. 65, 271–284 (2000)
24. M.D. Shultz, J.D. Wilson, C.E. Fuller, J. Zhang, H.C. Dorn, P.P. Fatouros,
Metallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging
in a murine orthotopic xenograft model. Radiology 261(1), 136–143 (2011)
25. H. Xie, B. Goins, A. Bao, Z.J. Wang, W.T. Phillips, Effect of intratumoral administration on
biodistribution of
64
Cu-labeled nanoshells. Int. J. Nanomed. 7, 2227–2238 (2012)
23 Therapeutic/Theranostic Use of Radionanomedicine
441